Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
最近の投稿
- 1
Famous SUVs With Low Energy Utilization In 2024 - 2The 20 Most sultry Style of the Time
- 3Deadly attack on kindergarten reported in Sudan
- 47 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- 5Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- Our 10 favorite Space.com reader astronomy photos of 2025
- Artemis 2 astronauts are now headed to the moon. Why has it taken humanity so long to go back?
- Lebanon says Israeli strike killed 13 people near Palestinian refugee camp
- Behind every perfect holiday memory is a mom on the brink
- Unfathomable and Entertaining Legal disputes That Surprise everyone
- VPN Administrations for Online Protection
- Alix Earle built trust by sharing her acne woes. Now her skin care line is raising questions.
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- Instructions to Explore the Universe of Vehicle Leases
